{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-012148","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.148052+00:00","generated_at":"2026-06-26T01:05:03.254045+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vericel Q1 revenue up 4% to $36.1M; net loss widens to $7.1M; reaffirms FY2022 guidance","bullets":["Total net revenue $36.1M (+4% YoY); MACI $26.0M, Epicel $9.9M, NexoBrid $0.2M.","Net loss $7.1M ($0.15/share) vs $3.3M loss a year ago; non-GAAP adj. EBITDA $3.2M.","Reaffirmed FY2022 guidance: revenue $178-189M, gross margin ~70%, adj. EBITDA margin ~21%.","MACI and Epicel biopsies growing double-digit; NexoBrid BLA resubmission on track for mid-2022.","Appointed Mike Gilligan as VP, MACI National Sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-012148","json":"https://secwatch.observer/filing/0001628280-22-012148.json","markdown":"https://secwatch.observer/filing/0001628280-22-012148.md","text":"https://secwatch.observer/filing/0001628280-22-012148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828022012148/0001628280-22-012148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828022012148/vcel-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:05:03.254045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}